WO2023042959A1 - 복합 진세노사이드 조성물을 포함하는 항염증 조성물 - Google Patents
복합 진세노사이드 조성물을 포함하는 항염증 조성물 Download PDFInfo
- Publication number
- WO2023042959A1 WO2023042959A1 PCT/KR2021/015893 KR2021015893W WO2023042959A1 WO 2023042959 A1 WO2023042959 A1 WO 2023042959A1 KR 2021015893 W KR2021015893 W KR 2021015893W WO 2023042959 A1 WO2023042959 A1 WO 2023042959A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginsenoside
- composition
- inflammatory
- complex
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 48
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 41
- 229940089161 ginsenoside Drugs 0.000 title claims description 31
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 25
- 239000012141 concentrate Substances 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 claims description 21
- 206010061218 Inflammation Diseases 0.000 claims description 18
- 230000004054 inflammatory process Effects 0.000 claims description 18
- 239000002131 composite material Substances 0.000 claims description 10
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 claims description 9
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims description 9
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 claims description 9
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 claims description 9
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 claims description 9
- 239000000606 toothpaste Substances 0.000 claims description 9
- 229940034610 toothpaste Drugs 0.000 claims description 9
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 claims description 8
- 239000002324 mouth wash Substances 0.000 claims description 8
- 229940051866 mouthwash Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 7
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 claims description 7
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 7
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 3
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 abstract description 8
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000005445 natural material Substances 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 235000008504 concentrate Nutrition 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000013521 mastic Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to an anti-inflammatory composition
- an anti-inflammatory composition comprising a complex ginsenoside composition extracted and processed from red ginseng, and a pharmaceutical composition, cosmetic, food, toothpaste, mouthwash, and the like containing the same.
- the present invention is the result of a task performed with the support of the Ministry of SMEs and Startups of the Republic of Korea (Task identification number: 1425147780, task title: Commercialization and efficacy test of red ginseng-specific saponin extract having anti-cavity efficacy).
- Inflammation refers to the body's response to injury, infection, or molecules recognized by the immune system as foreign substances. Inflammation is characterized by pain, swelling, or changes in function of tissues. Inflammatory diseases are characterized by abnormal levels of activation of the immune system in a tissue or organ, which can lead to dysfunction or disease in the tissue or organ.
- Inflammatory diseases are one of the leading causes of death worldwide. Inflammatory diseases affect many organs and tissues, such as blood vessels, heart, brain, nerves, joints, skin, lungs, eyes, gastrointestinal tract, kidneys, thyroid, adrenal glands, pancreas, liver and muscle. Treatment of inflammatory diseases is of interest to pharmaceutical companies and researchers. Despite many recent studies in this field, current therapies for inflammatory diseases are alleviating symptoms with non-specific drugs, reducing inflammation, and slowing disease progression, but these therapies have side effects and resistance to drugs. There is a serious problem.
- non-steroidal anti-inflammatory drugs are widely used as anti-inflammatory agents.
- nonsteroidal anti-inflammatory drugs are known to have serious side effects such as renal impairment, gastrointestinal disturbance, and liver failure (Rainsford KD., Subcell biochem., 42:3-27, 2007; Guruprasad P. Aithal., Rheumatology., 7:139-150, 2011; Praveen P. N. Rao et al., Pharmaceuticals., 3:1530-1549, 2010).
- the present invention aims to provide a natural substance composition that exhibits anti-inflammatory activity with little or no side effects, and reveals that ginsenosides extracted from ginseng and mixtures containing them exhibit anti-inflammatory effects, and based on this, provide strong anti-inflammatory substances. is to do
- the present invention is to provide food, medicine, cosmetics, mouthwash, toothpaste and the like using the above anti-inflammatory substances.
- the present inventors extracted complex ginsenosides from ginseng using a solvent, preferably an edible solvent, adsorbed them to an adsorbent resin, desorbed them with a solvent and partially purified them, and mixed red ginseng extract concentrates to obtain complex ginsenosides. After preparing the side composition, as a result of testing the anti-inflammatory activity, it was confirmed that the anti-inflammatory activity was remarkable.
- This composition can be used for preventing or treating oral inflammation such as stomatitis and gingivitis, toothpaste composition, skin external preparation, cosmetic composition, food, and the like.
- the composite ginsenoside composition of the present invention exhibited inhibition of NO production, inhibition of pro-inflammatory cytokine expression, and excellent anti-inflammatory activity.
- the complex ginsenoside composition of the present invention can be applied to an anti-inflammatory pharmaceutical composition, a toothpaste composition for preventing or treating oral inflammation, an oral composition including a mouthwash, an external skin composition for treating skin inflammation, a cosmetic composition, a food composition, and the like. .
- Figure 1 shows the results of NO production after 48 hours by inducing inflammation with LPS after treating BTEX-K samples by concentration (**p ⁇ 0.01, ***p ⁇ 0.001 compared to the control group).
- Figure 2 shows the results of pro-inflammatory cytokine production after 48 hours by inducing inflammation with LPS after treating BTEX-K samples by concentration (*p ⁇ 0.05, **p ⁇ 0.01 compared to the control group).
- Ginsenoside Rg3 (R+S), ginsenoside F2, ginsenoside Rh2, and ginsenoside Rb1 are each 7 parts by weight or more, preferably 30 parts by weight or more, based on 100 parts by weight of ginsenoside compound K. It relates to an anti-inflammatory composition containing, as an active ingredient, a complex ginsenoside composition containing 10 parts by weight or more and 30 parts by weight or less, more preferably 30 parts by weight or less.
- Red ginseng concentrate in step 4): fermented complex ginsenoside 1 ⁇ 9 : 9 ⁇ 1 (w/w), preferably 2 ⁇ 8 : 8 ⁇ 2, more preferably 3 ⁇ 7 : 7 ⁇ 3, more preferably 4_6: mixed in a ratio of 6 to 4, more preferably ginsenoside Rg3 (R + S), ginsenoside F2, ginsenoside Rh2 based on 100 parts by weight of ginsenoside compound K and ginsenoside Rb1 in an amount of 7 parts by weight or more, preferably 7 parts by weight or more and 30 parts by weight or less, more preferably 10 parts by weight or more and 30 parts by weight or less.
- the composite ginsenoside composition contains 20 parts by weight or more of ginsenoside Rg3 (R + S), 8 parts by weight or more of ginsenoside F2, 12 parts by weight of ginsenoside Rh2, based on 100 parts by weight of ginsenoside compound K. It relates to an anti-inflammatory composition characterized by containing at least 8 parts by weight of ginsenoside Rb1 and at least 8 parts by weight.
- the composite ginsenoside composition contains ginsenoside compound K of 100 mg/g or more, ginsenoside Rg3 (R+S), ginsenoside F2, ginsenoside Rh2, and ginsenoside Rb1 of 8 mg/g, respectively. g or more, preferably 8 mg/g or more and 30 mg/g or less, more preferably 10 mg/g or more and 30 mg/g or less.
- the adsorption resin column is not particularly limited, but is preferably a porous adsorption resin column, more preferably at least one of HP2MG and HP-20.
- the present invention relates to an anti-inflammatory composition characterized in that the red ginseng concentrate in steps 1), 2) and 4) is in powder form or liquid form.
- the present invention relates to a composition for external application for skin for treating skin inflammation comprising the anti-inflammatory composition.
- the present invention relates to a cosmetic composition comprising the anti-inflammatory composition.
- the present invention relates to a pharmaceutical composition for preventing or treating inflammation comprising the anti-inflammatory composition.
- the pharmaceutical composition may be one or more formulations selected from the group consisting of oral formulations, external preparations, suppositories, sterile injection solutions, and sprays.
- the present invention relates to a toothpaste composition for preventing or improving oral inflammation comprising the anti-inflammatory composition.
- the present invention relates to a mouthwash composition for preventing or improving oral inflammation comprising the anti-inflammatory composition.
- the present invention relates to a food composition for preventing or improving inflammation comprising the anti-inflammatory composition.
- the term "food” used in the present invention means a natural product or processed product containing one or more nutrients, and preferably means a product that can be eaten directly through a certain degree of processing process. As a meaning, it may include all foods, food additives, functional foods, health functional foods, health supplement foods, and beverages.
- the food composition of the present invention may be prepared in the form of various beverages, chewing gum, tea, sweets, vitamin complexes, health supplements, and the like, without limitation.
- the preferred intake amount of the food composition of the present invention varies depending on the condition, body weight, severity of symptoms, food type, and intake period of the person who consumes it, and may be appropriately selected. In the food composition of the present invention, it is preferable for optimal effect that the active ingredient be ingested at 0.2 mg/kg to 200 mg/kg per day.
- the anti-inflammatory composition containing the complex ginsenoside composition as an active ingredient can be formulated with a carrier commonly accepted in the pharmaceutical field and formulated into an injection form, oral administration, or coating form by conventional methods.
- a carrier commonly accepted in the pharmaceutical field
- it can be formulated into a liquid, syrup, capsule, granule, powder, ointment, emulsion, gel, cream, etc., and can be administered through various routes.
- injectable compositions preferably isotonic aqueous solutions or suspensions
- the mentioned compositions are sterile and/or contain additives such as preservatives, stabilizers, wetting agents or emulsifiers, solution accelerators, salts and/or buffers for regulating osmotic pressure.
- compositions may contain other therapeutically useful substances.
- Pharmaceutically acceptable carriers include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, These include methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- the composition may further include lubricants, wetting agents, flavoring agents, emulsifying agents and preservatives.
- the composition of the present invention may be formulated into oral formulations such as granules, powders, solutions, tablets, capsules, or dry syrups, or parenteral formulations such as injections, but is not limited to these formulations.
- the pharmaceutical preparation prepared as described above may be administered by subcutaneous administration, intramuscular administration or oral administration, intravenous administration, skin application, oral application, gum application, etc., depending on the purpose, and the daily dosage is 0.001 ⁇ g / kg ⁇ 100
- the amount of mg/kg may be administered in one to several divided doses.
- the dosage level for a specific patient may vary depending on the patient's weight, age, sex, health condition, administration time, administration method, severity of disease, and the like.
- the anti-inflammatory composition containing the complex ginsenoside composition as an active ingredient is characterized in that it is an external preparation for skin inflammation treatment.
- a coating agent containing the anti-inflammatory composition of the present invention as an active ingredient can be easily prepared in any form according to a conventional manufacturing method.
- the anti-inflammatory composition of the present invention is contained in a general oil-in-water (O/W) or water-in-oil (W/O) cream base, and there are fragrances, chelating agents, pigments, antioxidants, While preservatives are used as needed, synthetic or natural materials such as proteins, minerals, and vitamins may be used in combination for the purpose of improving physical properties.
- the present invention relates to a cosmetic composition containing an anti-inflammatory composition containing the composite ginsenoside composition as an active ingredient as a main component. It can be formulated into lotion, gel, water-soluble powder, fat-soluble powder, water-soluble liquid, cream, essence, etc. by adding a pH adjusting agent, fragrance, emulsifier, preservative, etc. as needed.
- the present invention relates to a toothpaste composition for preventing or improving oral inflammation containing the complex ginsenoside composition as an active ingredient.
- Mastic oil, propolis extract, sodium pyrophosphate, sodium fluoride, tocopherol acetate, hydroxyapatite, sweetener, thickener, abrasive, humectant, or surfactant may be added as necessary to formulate a toothpaste composition in a conventional method.
- the present invention relates to an oral composition for preventing or improving oral inflammation containing the complex ginsenoside composition as an active ingredient.
- a solubilizer, a wetting agent, a surfactant, a lubricant, a flavoring agent, a sweetener, a preservative or a medicinal agent may be added as necessary and formulated according to a conventional oral composition manufacturing method, and gum, mouthwash, mouthwash, It may be prepared as a formulation selected from the group consisting of an oral spray, an oral ointment, an oral patch, or a combination thereof.
- alpha-galactosidase (0.75 g) derived from the genus Aspergillus in 50 mM sodium acetate buffer (pH 4.5) and 84 hours in a constant temperature water bath at 60 ° C.
- a fermentation complex ginsenoside 41 g was prepared.
- the fermented complex ginsenoside prepared in this way includes ginsenoside compound K, ginsenoside F2, ginsenoside Rh2, and the like.
- Example 4 Preparation of a composite ginsenoside composition (hereinafter mixed with "BTEX-K")
- a complex ginsenoside composition BTEX-K was prepared by mixing 40 g of the red ginseng concentrate powder prepared in Example 2 with 100 g of the fermented complex ginsenoside prepared in Example 3.
- the suspended cells were seeded in a well plate at 8 ⁇ 10 3 per well, and then cultured in a CO 2 incubator for 24 hours.
- a calibration curve was prepared using sodium nitrite solution, and the concentration of nitrite was calculated through absorbance.
- the suspended cells were seeded in a 96-well plate at an amount of 8 ⁇ 10 3 cells per well and cultured in a CO 2 incubator for 24 hours.
- the solvent in which the sample is dissolved is ethanol
- the cell viability of Raw 264.7 cells against ethanol was investigated. Ethanol was added to the Raw 264.7 cell culture solution by concentration, followed by culturing for 24 hours, and as a result of MTT analysis, it was confirmed that at an ethanol concentration of 2% or more, more than 40% of the Raw264.7 cells were killed. Therefore, the ethanol concentration of the sample solvent was fixed to 1% or less.
- sample BTEX-K was administered according to concentration to confirm the cell viability of Raw 264. It was confirmed that the viability of Raw 264.7 cells decreased from the BTEX-K concentration of 30 ug/ml. Therefore, the following experiments were performed by fixing the BTEX-K sample concentration to 5, 10 and 20 ug/ml.
- Raw 264.7 cells were treated with LPS, an inflammation-inducing reagent, at each concentration, and cell viability and NO production were tested.
- Cell viability increased at LPS concentrations of 100 ng/ml and 200 ng/ml, and NO production increased only at 100 ng/ml LPS concentration. Therefore, the experiment was conducted by confirming the concentration of LPS as 100 ng/ml.
- Raw 264.7 cells were treated with BTEX-K at different concentrations, cultured for 24 hours, and 100 ng/ml of LPS was added to confirm cytokine production after 48 hours. A significant decrease in -1 ⁇ was confirmed respectively (*p ⁇ 0.05, **p ⁇ 0.01).
- the viability of Raw 264.7 cells was confirmed according to the concentrations of ginsenoside compound K and BTEX-K, and appropriate concentrations to be used in the experiment were determined. As a result, it was confirmed that ginsenoside compound K decreased the viability of Raw 264.7 cells at a concentration of 20 ug/ml, and BTEX-K decreased viability of Raw 264.7 cells at a concentration of 30 ug/ml. Therefore, the appropriate concentrations of the anti-inflammatory test to be performed thereafter were fixed at 1, 5, and 10 ug/ml for ginsenoside compound K and 5, 10, and 20 ug/ml for BTEX-K.
- the composite ginsenoside composition of the present invention can be applied to an anti-inflammatory pharmaceutical composition, a toothpaste composition for preventing or treating oral inflammation, an oral composition including a mouthwash, an external skin composition for treating skin inflammation, a cosmetic composition, a food composition, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
BTEX-K 중 주요 진세노사이드 함량 (10mg/g 이상) | |||||
진세노사이드 | Rb1 | F2 | Rg3(R+S) | Rh2 | Compound K |
함량(mg/g) | 11.5 | 11.5 | 25.5 | 15.4 | 100 |
번호 | 시료 | 농도 |
1 | 진세노사이드 화합물 K | 1, 5, 10, 20 ㎍/㎖ |
2 | BTEX-K | 5, 10, 20, 30, 40, 50, 100 ㎍/㎖ |
번호 | 시료 | 농도 |
1 | 진세노사이드 화합물 K | 1, 5, 10 ㎍/㎖ |
2 | BTEX-K | 5, 10, 20 ㎍/㎖ |
번호 | 시료 | 농도 |
1 | 진세노사이드 화합물 K | 1, 5, 10 ㎍/㎖ |
2 | BTEX-K | 5, 10, 20 ㎍/㎖ |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180102314.0A CN117999080A (zh) | 2021-09-14 | 2021-11-04 | 包含复合人参皂苷组合物的抗炎组合物 |
JP2024516622A JP2024533530A (ja) | 2021-09-14 | 2021-11-04 | 複合ジンセノシド組成物を含む抗炎症組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210122350A KR20230039856A (ko) | 2021-09-14 | 2021-09-14 | 복합 진세노사이드 조성물을 포함하는 항염증 조성물 |
KR10-2021-0122350 | 2021-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023042959A1 true WO2023042959A1 (ko) | 2023-03-23 |
Family
ID=85603018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/015893 WO2023042959A1 (ko) | 2021-09-14 | 2021-11-04 | 복합 진세노사이드 조성물을 포함하는 항염증 조성물 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2024533530A (ko) |
KR (1) | KR20230039856A (ko) |
CN (1) | CN117999080A (ko) |
WO (1) | WO2023042959A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117323270A (zh) * | 2023-11-29 | 2024-01-02 | 江西康一参生物科技有限公司 | 一种抗炎症多功效的人参组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090087709A (ko) * | 2008-02-13 | 2009-08-18 | 주식회사 한국인삼공사 | 사포닌을 유효성분으로 포함하는 치주질환의 치료용 조성물 |
KR101566589B1 (ko) * | 2013-11-22 | 2015-11-06 | 경희대학교 산학협력단 | 진세노사이드 f2의 함량이 증가된 발효 홍삼의 제조방법 및 상기 방법으로 제조된 발효 홍삼 추출물 |
KR20160124007A (ko) * | 2015-04-17 | 2016-10-26 | 주식회사유한양행 | 염증성 질환 또는 통증 예방 또는 치료용 조성물 |
KR102019330B1 (ko) * | 2012-05-25 | 2019-09-10 | 한국과학기술연구원 | 마이크로웨이브 조사에 의해 진세노사이드 알지3, 알지5 및 알케이1의 함량비율이 증가된 파낙스속 식물 추출물, 그 제조방법, 및 그 가공 파낙스속 식물 추출물을 포함하는 조성물 |
KR102118998B1 (ko) * | 2018-08-14 | 2020-06-04 | 주식회사 비티진 | 충치균의 생육억제 작용을 갖는 진세노사이드 및 조성물 |
-
2021
- 2021-09-14 KR KR1020210122350A patent/KR20230039856A/ko not_active Application Discontinuation
- 2021-11-04 JP JP2024516622A patent/JP2024533530A/ja active Pending
- 2021-11-04 CN CN202180102314.0A patent/CN117999080A/zh active Pending
- 2021-11-04 WO PCT/KR2021/015893 patent/WO2023042959A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090087709A (ko) * | 2008-02-13 | 2009-08-18 | 주식회사 한국인삼공사 | 사포닌을 유효성분으로 포함하는 치주질환의 치료용 조성물 |
KR102019330B1 (ko) * | 2012-05-25 | 2019-09-10 | 한국과학기술연구원 | 마이크로웨이브 조사에 의해 진세노사이드 알지3, 알지5 및 알케이1의 함량비율이 증가된 파낙스속 식물 추출물, 그 제조방법, 및 그 가공 파낙스속 식물 추출물을 포함하는 조성물 |
KR101566589B1 (ko) * | 2013-11-22 | 2015-11-06 | 경희대학교 산학협력단 | 진세노사이드 f2의 함량이 증가된 발효 홍삼의 제조방법 및 상기 방법으로 제조된 발효 홍삼 추출물 |
KR20160124007A (ko) * | 2015-04-17 | 2016-10-26 | 주식회사유한양행 | 염증성 질환 또는 통증 예방 또는 치료용 조성물 |
KR102118998B1 (ko) * | 2018-08-14 | 2020-06-04 | 주식회사 비티진 | 충치균의 생육억제 작용을 갖는 진세노사이드 및 조성물 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117323270A (zh) * | 2023-11-29 | 2024-01-02 | 江西康一参生物科技有限公司 | 一种抗炎症多功效的人参组合物及其应用 |
CN117323270B (zh) * | 2023-11-29 | 2024-03-19 | 江西康一参生物科技有限公司 | 一种抗炎症多功效的人参组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117999080A (zh) | 2024-05-07 |
KR20230039856A (ko) | 2023-03-22 |
JP2024533530A (ja) | 2024-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010134756A2 (ko) | 녹차 추출물을 함유하는 조성물 | |
WO2015026114A1 (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
WO2010137846A2 (ko) | 사포닌의 생체 이용률 증진 조성물 | |
WO2014084572A1 (ko) | 사이클로덱스트린을 포함하는 카테킨 생체 이용률 증진제 | |
WO2018128408A1 (ko) | 바이칼레인을 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물 | |
WO2015002391A1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
WO2017014502A1 (ko) | 해당화 꽃 추출물을 유효성분으로 포함하는 il-6 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019088446A1 (ko) | 산수국 추출물을 함유하는 자외선에 의한 인간 피부세포 손상 개선용 조성물 | |
WO2023177188A1 (ko) | 당 확산 추출공법으로 추출한 생병풀 추출물을 포함하는 항염, 장벽 효능을 가지는 화장료 조성물 및 이의 용도 | |
WO2023042959A1 (ko) | 복합 진세노사이드 조성물을 포함하는 항염증 조성물 | |
WO2017191856A1 (ko) | 지페노사이드 75의 항당뇨 효과 | |
WO2011019174A2 (ko) | 항산화 및 미백 효능을 갖는 막걸리 농축액 함유 조성물 | |
WO2018190501A1 (ko) | 인삼 꽃대 추출물을 포함하는 항염증용 조성물 | |
WO2015034247A1 (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
US6440451B1 (en) | Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases | |
WO2013115456A1 (ko) | 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품, 화장료 또는 약학 조성물 | |
WO2011008001A2 (ko) | 진세노사이드 강화 분획물을 포함하는 혈압 강하용 조성물 | |
WO2018062801A1 (ko) | 코스모페린을 포함하는 항스트레스 조성물 | |
WO2021187905A1 (ko) | 천화분, 백선피 및 상백피를 포함하는 암 및 내성암에 대한 약학적 조성물 | |
WO2019156498A1 (ko) | 가시박 추출물을 유효성분으로 함유하는 항암제 부작용에 의한 질환의 예방, 개선 또는 치료용 조성물 | |
US20160367719A1 (en) | Fractions of extracts of helichrysum having mucohadhesive properties | |
WO2018062800A1 (ko) | 에스쿨린을 포함하는 항스트레스 조성물 | |
WO2023113139A1 (ko) | 진세노사이드 화합물 k 또는 복합 진세노사이드 조성물을 포함하는 치면 세균막 감소 및 치면 세균막 산성화 억제용 조성물 | |
WO2021070999A1 (ko) | 비만, 당뇨, 고지혈증 및 지방간을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 | |
KR100278361B1 (ko) | 골다공증 예방 및 치료용 약제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21957627 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180102314.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2024516622 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21957627 Country of ref document: EP Kind code of ref document: A1 |